Encompass Health Corp (NYSE:EHC) Expected to Announce Quarterly Sales of $1.07 Billion

Wall Street brokerages forecast that Encompass Health Corp (NYSE:EHC) will report $1.07 billion in sales for the current quarter, Zacks reports. Seven analysts have provided estimates for Encompass Health’s earnings, with the highest sales estimate coming in at $1.17 billion and the lowest estimate coming in at $1.00 billion. Encompass Health reported sales of $1.14 billion during the same quarter last year, which would suggest a negative year over year growth rate of 6.1%. The company is expected to announce its next quarterly earnings results after the market closes on Monday, July 27th.

On average, analysts expect that Encompass Health will report full-year sales of $4.69 billion for the current fiscal year, with estimates ranging from $4.61 billion to $4.84 billion. For the next year, analysts expect that the business will post sales of $5.20 billion, with estimates ranging from $5.10 billion to $5.26 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Encompass Health.

Encompass Health (NYSE:EHC) last issued its earnings results on Tuesday, April 28th. The company reported $0.87 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.87. Encompass Health had a return on equity of 22.00% and a net margin of 7.36%. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.20 billion.

EHC has been the topic of a number of recent research reports. Stephens increased their target price on Encompass Health from $91.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, March 5th. UBS Group decreased their price objective on Encompass Health from $96.00 to $90.00 and set a “buy” rating for the company in a report on Friday, May 1st. Robert W. Baird lifted their price objective on Encompass Health from $85.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, March 5th. Raymond James decreased their price objective on Encompass Health from $90.00 to $86.00 and set an “outperform” rating for the company in a report on Thursday, April 30th. Finally, Mizuho lifted their price objective on Encompass Health from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $91.78.

Shares of EHC traded up $1.37 during trading hours on Monday, reaching $60.68. The stock had a trading volume of 658,484 shares, compared to its average volume of 811,542. Encompass Health has a 12 month low of $48.01 and a 12 month high of $83.30. The firm has a 50-day simple moving average of $68.94 and a 200 day simple moving average of $70.59. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 1.98. The company has a market capitalization of $5.90 billion, a price-to-earnings ratio of 17.31, a P/E/G ratio of 6.80 and a beta of 0.88.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be paid a $0.28 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $1.12 annualized dividend and a yield of 1.85%. Encompass Health’s dividend payout ratio is currently 28.64%.

Encompass Health Company Profile

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Recommended Story: Neutral Rating

Get a free copy of the Zacks research report on Encompass Health (EHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.